trending Market Intelligence /marketintelligence/en/news-insights/trending/_t0jxy8rtl3yjyxfmixmjw2 content esgSubNav
In This List

Nektar Therapeutics Q1 loss widens YOY

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Nektar Therapeutics Q1 loss widens YOY

Nektar Therapeutics said its net loss for the first quarter was 60 cents per share, compared with the S&P Capital IQ consensus normalized EPS estimate of a loss of 55 cents per share.

The per-share loss grew 42.9% year over year from 42 cents.

Net loss totaled $95.8 million, compared with a loss of $63.9 million in the prior-year period.

In April, the company completed a multibillion-dollar strategic development deal with Bristol-Myers Squibb Co. The company said the proceeds from the deal were not included in this quarter's reporting.

Total revenue grew 53.7% on an annual basis to $38.0 million from $24.7 million, and total operating costs and expenses climbed 57.6% year over year to $124.8 million from $79.2 million.